Abstracts tagged "treatment"

Abstract Number: L06 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards
Mark C. Genovese¹, Kenneth C. Kalunian², David Walker³, Jacques-Eric Gottenberg⁴, Kurt de Vlam⁵, Neelufar Mozaffarian⁶, Beatrix Bartok⁶, Franziska Matzkies⁶, Jie Gao⁶, Ying Guo⁶, Chantal Tasset⁷, John S. Sundy⁶ and Tsutomu Takeuchi⁸, ¹Division of Immunology & Rheumatology, Stanford University, Stanford, CA, ²Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ³Northumbria Healthcare, United Kingdom, United Kingdom, ⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁶Gilead Sciences, Inc., Foster City, CA, ⁷Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, ⁸Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in phase 2 studies of active RA in patients (pts) with insufficient…
Abstract Number: 1526 • 2018 ACR/ARHP Annual Meeting
Baseline Characteristics and Outcomes in Patients with Anemia in Clinical Studies of Tofacitinib
Burkhard Moeller¹, Axel Finckh², Jose Maria Alvaro-Gracia³, Godehard Scholz¹, Daniel Aletaha⁴, Francesca Biondo⁵, Sander Strengholt⁶, Jose L Rivas⁷, Carol A Connell⁸ and Harry Shi⁹, ¹Inselspital-University Hospital, Bern, Switzerland, ²University Hospital of Geneva, Geneva, Switzerland, ³Hospital Universitario de La Princesa, Madrid, Spain, ⁴Medical University of Vienna, Vienna, Austria, ⁵Pfizer Inc, Rome, Italy, ⁶Pfizer Inc, Capelle aan den IJssel, Netherlands, ⁷Pfizer SLU, Madrid, Spain, ⁸Pfizer Inc, Groton, CT, ⁹Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The purpose of this study is to describe the profile of patients…
Abstract Number: 1538 • 2018 ACR/ARHP Annual Meeting
Moderate Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis
Lydia A Alcazar¹, Dalifer Freites Núñez¹, Isabel Hernández-Rodríguez², Judit Font Urgelles², Pia Mercedes Lois², Benjamín Fernández-Gutiérrez², Juan A Jover Jover¹ and Zulema Rosales Rosado^1,2, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: In rheumatology, we are aware of the possibility to develop adverse drug reactions (ADR) to the widely used Disease Modifying Drugs (DMARD). We are…
Abstract Number: 1539 • 2018 ACR/ARHP Annual Meeting
Safety of Methotrexate and Leflunomide Combination Therapy in the Treatment of Rheumatoid Arthritis
María Badilla¹, Nicia Moldenhauer², Diego Neira³, Luis Muñoz⁴ and Oscar Neira¹, ¹Rheumatology Section., Hospital del Salvador, Universidad de Chile., Santiago, Chile, ²Rheumatology Section, Hospital del Salvador, Universidad de Chile, Santiago, Chile, ³Internal Medicine Departament, Hospital del Salvador, Universidad de Chile, Santiago, Chile, ⁴Pharmacy Department, Hospital del Salvador, Santiago, Chile
Background/Purpose: Best treatment of Rheumatoid Arthritis (RA) requires to begin early, with a tight control, including nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, disease-modifying antirheumatic drugs (DMARDs)…
Abstract Number: 2038 • 2018 ACR/ARHP Annual Meeting
Subgroups By the Peripheral Immunophenotyping and Different Responses to Biological Dmards in Patients with Rheumatoid Arthritis
Satoshi Kubo¹, Shingo Nakayamada¹, Yusuke Miyazaki¹, Maiko Yoshikawa², Hiroko Yoshinari³, Shigeru Iwata⁴, Kentaro Hanami², Shunsuke Fukuyo³, Ippei Miyagawa⁵, Kazuhisa Nakano¹ and Yoshiya Tanaka⁶, ¹First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³University of Occupational and Environmental Health, Japan, Fukuoka, Japan, ⁴First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: In the treatment of rheumatoid arthritis (RA), molecular targeted therapies induced different changes in different immune cell phenotypes. For instance, our previous study showed…
Abstract Number: 50 • 2018 ACR/ARHP Annual Meeting
Intra-Articularly Delivering Lentivirus-Based CRISPR Interference Targeting Long Non-Coding RNA H19 in Synovial Fibroblasts Ameliorates Experimental Arthritis
Chrong-Reen Wang¹, Shih-Yao Chen², Yu-Ting Lo³, Yu-Chi Chou⁴, Ming-Fei Liu¹, Chao-Liang Wu⁵ and Ai-Li Shiau³, ¹Internal Medicine, National Cheng Kung University Hospital and Medical College, Tainan, Taiwan, ²Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan, ³Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan, ⁴Core Facility for Manipulation of Gene Function, Academia Sinica, Taipei, Taiwan, ⁵Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan
Background/Purpose: Aberrantly higher expression of long non-coding RNAs (lncRNAs) in synovial fibroblasts (SFs) plays pathogenic roles in rheumatoid joint. Studying the effects on knocking down…
Abstract Number: 2172 • 2018 ACR/ARHP Annual Meeting
Overuse of Glucocorticoids in Rheumatoid Arthritis: A National Survey of Primary Care Physicians
Beth Wallace^1,2, Akbar Waljee^2,3,4, Arlene Weissman⁵, Tanner Caverly^2,6,7 and Sameer Saini^2,6,8, ¹Department of Internal Medicine, Division of Rheumatology, Michigan Medicine, Ann Arbor, MI, ²University of Michigan Institute for Healthcare Policy and Innovation, Ann Arbor, MI, ³Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁴Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, MI, ⁵Research Center at American College of Physicians, Philadelphia, PA, ⁶Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI, ⁷Michigan Medicine Department of Internal Medicine, Division of General Medicine, Ann Arbor, MI, ⁸Michigan Medicine Department of Internal Medicine, Division of Gastroenterology and Hepatology, Ann Arbor, MI
Background/Purpose: Most patients with RA receive oral glucocorticoids (GC) such as prednisone, despite concerns about safety. We sought to evaluate how primary care physicians (PCPs)…
Abstract Number: 553 • 2018 ACR/ARHP Annual Meeting
Channeling to Treatment and Associated Changes in Disease Activity Over 12 Months in Patients With RA Treated With Abatacept Versus Other DMARDs in Real-World Community Practice Settings
Leticia Ferri¹, Jeffrey R. Curtis², Ying Bao¹, Evo Alemao¹, Tammy Curtice¹, Joshua Bryson¹, Karissa Lozenski¹, Sandhya Balachandar¹ and Varshini Rajagopalan³, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Alabama at Birmingham, Birmingham, AL, ³Mu Sigma, Bangalore, India
Background/Purpose: Abatacept (ABA), a selective T-cell co-stimulatory modulator, has shown efficacy similar to TNF inhibitors (TNFi) for RA management in clinical trial settings, but different…
Abstract Number: 2488 • 2018 ACR/ARHP Annual Meeting
Characteristics of Difficult-to-Treat Rheumatoid Arthritis: Results of an International Survey
Nadia MT Roodenrijs¹, Maria JH de Hair¹, Marlies C van der Goes¹, Johannes W. G. Jacobs¹, Paco MJ Welsing¹, Désirée van der Heijde², Daniel Aletaha³, Maxime Dougados⁴, Kimme L. Hyrich⁵, Iain B. McInnes⁶, Ulf Müller-Ladner⁷, Ladislav Šenolt⁸, Zoltan Szekanecz⁹, Jacob van Laar¹ and Gyorgy Nagy¹⁰, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁴Department of Rheumatology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris Descartes University, Paris, France, Paris, France, ⁵Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁶Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK, Glasgow, United Kingdom, ⁷Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Germany, Bad Nauheim, Germany, ⁸First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁹Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, Debrecen, Hungary, ¹⁰Department of Genetics, Cell- and Immunobiology & Department of Rheumatology, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary, Budapest, Hungary
Background/Purpose: EULAR and ACR recommendations on the management of rheumatoid arthritis (RA) mainly focus on early RA and medication.1,2 Following these recommendations, several patients nevertheless…
Abstract Number: 557 • 2018 ACR/ARHP Annual Meeting
The Impact of Comedication with Conventional Synthetic Dmards on Drug Retention and Clinical Effectiveness of Tofacitinib, Anti–Tumor Necrosis Factor Therapy and Biologics with an Alternative Mode of Action in Patients with Rheumatoid Arthritis. a Cohort Study
Axel Finckh¹, Christophe Tellenbach², Almut Scherer², Burkhard Moeller³, Adrian Ciurea⁴, Ines von Mühlenen⁵, Cem Gabay⁶, Diego Kyburz⁷, Ruediger Mueller⁸, Paul Hasler⁹ and Pascal Zufferey¹⁰, ¹University Hospital of Geneva, Geneva, Switzerland, ²SCQM Foundation, Zurich, Switzerland, ³Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Rheuma-Basel, Basel, Switzerland, ⁶University Hospitals of Geneva, Geneva, Switzerland, ⁷Rheumatology, University Hospital Basel, Basel, Switzerland, ⁸Division of Rheumatology, Kantonsspital St Gallen, St. Gallen, Switzerland, ⁹Kantonsspital Aarau AG, Aarau, Switzerland, ¹⁰Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland
Background/Purpose: Co-medication with conventional synthetic DMARDs (csDMARDs) is currently recommended with all targeted therapies (bDMARDs and tsDMARDs) for the management of rheumatoid arthritis (RA). However,…
Abstract Number: 2519 • 2018 ACR/ARHP Annual Meeting
Exposure-Efficacy Analysis in DMARD Inadequate Response Rheumatoid Arthritis Patients Treated with GSK3196165 Along with Methotrexate
Anubha Gupta¹, Chiara Zecchin¹, Elena Fisheleva^1,2, Mark Layton³ and Stefano Zamuner⁴, ¹GlaxoSmithKline, Stevenage, United Kingdom, ²Currently at Biomarin UK Ltd, London, United Kingdom, ³ImmunoInflammation, ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ⁴Clinical Pharmacology, GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: GSK3196165 is an anti-GM-CSF mAb being developed for RA. In a phase IIb dose-finding study (NCT02504671), RA patients with inadequate response to methotrexate were…
Abstract Number: 574 • 2018 ACR/ARHP Annual Meeting
Longitudinal Efficacy Analysis of Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Dmards: Response Following Rescue from Baricitinib 2mg to 4mg Once-Daily
Roy Fleischmann¹, Mark C. Genovese², Anabela Cardoso³, Luna Sun³, Yun-Fei Chen³, Chad D. Walls³, Douglas E. Schlichting³, Tsutomu Takeuchi⁴, Maxime Dougados⁵, Josef S. Smolen⁶ and Jeffrey R. Curtis⁷, ¹Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, ²Stanford University Medical Center, Palo Alto, CA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keio University School of Medicine, Tokyo, Japan, ⁵Paris Descartes University, Hôpital Cochin, Paris, France, ⁶Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Baricitinib (bari), an oral selective Janus kinase 1/2 inhibitor, has shown clinical efficacy in patients (pts) with RA and an inadequate response to conventional…
Abstract Number: 2551 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study
Arthur Kavanaugh¹, Mark C. Genovese², Kevin Winthrop³, Maria Greenwald⁴, Lucia Ponce⁵, Favio Enriquez Sosa⁶, Mykola Stanislavchuk⁷, Minodora Mazur⁸, Alberto Spindler⁹, Regina Cseuz¹⁰, Natalya Nikulenkova¹¹, Maria Glowacka-Kulesz¹², Istvan Szombati¹³, Anna Dudek¹⁴, Neelufar Mozaffarian¹⁵, Joy Greer¹⁶, Rebecca Kunder¹⁵, Di An¹⁷, Luc Meuleners¹⁸, Robin Besuyen¹⁸, Rieke Alten¹⁹ and René Westhovens²⁰, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Stanford University Medical Center, Palo Alto, CA, ³Oregon Health and Science University, Portland, OR, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Cons. Priv. Temuco, Temuco, Chile, ⁶Clinstile SA de CV, Col., Mexico City, Mexico, ⁷Rheumatology, Vinnytsia Regional Clinical Hospital, Vinnytsia, Ukraine, ⁸IMSP Inst. de Cardiologie, Chisinau, Moldova, The Republic of, ⁹Centro Médico Privado de Reumatología, Centro Médico Privado de Reumatología, Argentina, ¹⁰Revita Reumatologiai Kft, Budapest, Hungary, ¹¹Vladimir Reg Clin Hosp, Vladimir, Russian Federation, ¹²Silesiana Centrum Medyczne, Wroclawska, Poland, ¹³Qualiclinic Kft., Budapest, Hungary, ¹⁴AMED Medical Center, Warsaw, Poland, ¹⁵Gilead Sciences, Inc., Foster City, CA, ¹⁶Gilead Sciences, Inc, Foster City, CA, ¹⁷Gilead Science, Inc., Foster City, CA, ¹⁸Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, ¹⁹Schlosspark-Klinik University Medicine, Berlin, Germany, ²⁰Rheumatology, University Hospital KU Leuven, Leuven, Belgium
Background/Purpose: The orally administered, selective inhibitor of Janus Kinase 1 (JAK1), filgotinib (FIL), is currently being investigated for the treatment of rheumatoid arthritis (RA) in…
Abstract Number: 575 • 2018 ACR/ARHP Annual Meeting
Time to Discontinuation of Biologic Therapy By Mechanism of Action in Rheumatoid Arthritis: Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Elliot Hepworth², Reza Mirza², Angela Cesta³, Maggie Larche⁴ and Claire Bombardier^1,5,6, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Internal Medicine, McMaster University, Hamilton, ON, Canada, ³Ontario Best Practices Research Initiative, University Health Network, Toronto, ON, Canada, ⁴Medicine, McMaster University, Hamilton, ON, Canada, ⁵University of Toronto, Department of Medicine (DOM) and Institute of Health Policy Management, and Evaluation (IHPME), Toronto, ON, Canada, ⁶Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) may discontinue their biologic disease modifying antirheumatic drug (bDMARDs) due to non-response, loss of response or adverse events. However,…
Abstract Number: 2822 • 2018 ACR/ARHP Annual Meeting
Should We Prefer Leflunomide to Methotrexate in Combination with Biologics? a Systematic Review and a Meta-Analysis
Guillaume Decarriere¹, Thomas Barnetche², Cédric Lukas³, Cécile Gaujoux-Viala⁴, Bernard Combe⁵, Jacques Morel⁶ and Claire I. Daien⁷, ¹Department of Rheumatology, CHU Lapeyronie, Montpellier, France, ²Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ⁵Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁶Department of Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁷Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: In rheumatoid arthritis (RA), biologics are more efficient in combination with methotrexate (MTX) than in monotherapy. When MTX cannot be used, others csDMARD can…

« Previous Page
1
…
5
6
7
8
9
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.